Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 22Neoplasms 5Neoplasm Metastasis 2Urachal cancer 1Stomach Neoplasms 1Rectal Neoplasms 1Pancreatic Cancer Metastatic 1Gastro-enteropancreatic neuroendocrine tumor 1Diabetes Mellitus, Insulin-Dependent, 12 1Cholangiocarcinoma 1Carcinoma, Pancreatic Ductal 1Carcinoma, Islet Cell 1Carcinoma, Hepatocellular 1Borderline Resectable Pancreatic Cancer 1Biliary Tract Neoplasms 1Adenocarcinoma 1

Interventions

Bevacizumab 69Sorafenib 66lenvatinib 59durvalumab 38sintilimab 33Nivolumab 32tislelizumab 28atezolizumab 28pembrolizumab 27Oxaliplatin 26tremelimumab 23apatinib 22Fluorouracil 22Radiosurgery 20regorafenib 19camrelizumab 18Doxorubicin 18cabozantinib 16Leucovorin 16Capecitabine 16Radiotherapy 14Folfox protocol 14donafenib 13Gemcitabine 13Cisplatin 12toripalimab 11Erlotinib Hydrochloride 10spartalizumab 8anlotinib 8Neoadjuvant Therapy 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma, Hepatocellular × folfirinox × Clear all
NCT03812783 2019-01-23

HAIC of FOLFOX Plus Sorafenib vs HAIC of FOLFIRINOX Plus Sorafenib for Advcanced HCC

Sun Yat-sen University

Phase 2 Unknown
100 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡